Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0033774 (
pruritus
)
14,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tazarotene (Tazorac, Allergan, Inc.) is the first topical retinoid approved for the treatment of plaque psoriasis. It has a similar onset of action compared to potent topical steroids and has the advantage of a longer remission. The common side effects associated with the drug include
skin irritation
(including
pruritus
), erythema and a burning sensation. To overcome some of these shortcomings, it has been used in combination with steroids, calcipotriene and phototherapy. Combination therapy not only results in a decrease in adverse side effects, but also enhanced efficacy. Clinical study data have shown that combination therapy is just as important as tazarotene monotherapy, if not more.
...
PMID:The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. 1464 Sep 32
Cleanser technology has come a long way from merely cleansing to providing mildness and moisturizing benefits as well. It is known that harsh surfactants in cleansers can cause damage to skin proteins and lipids, leading to after-wash tightness, dryness, barrier damage, irritation, and even
itch
. In order for cleansers to provide skin-care benefits, they first must minimize surfactant damage to skin proteins and lipids. Secondly, they must deposit and deliver beneficial agents such as occlusives, skin lipids, and humectants under wash conditions to improve skin hydration, as well as mechanical and visual properties. While all surfactants tend to interact to some degree with lipids, their interaction with proteins can vary significantly, depending upon the nature of their functional head group. In vitro, ex vivo, and in vivo studies have shown that surfactants that cause significant
skin irritation
interact strongly with skin proteins. Based on this understanding, several surfactants and surfactant mixtures have been identified as "less irritating" mild surfactants because of their diminished interactions with skin proteins. Surfactants that interact minimally with both skin lipids and proteins are especially mild. Another factor that can aggravate surfactant-induced dryness and irritation is the pH of the cleanser. The present authors' recent studies demonstrate that high pH (pH 10) solutions, even in the absence of surfactants, can increase stratum corneum (SC) swelling and alter lipid rigidity, thereby suggesting that cleansers with neutral or acidic pH, close to SC-normal pH 5.5, may be potentially less damaging to the skin. Mildness enhancers and moisturizing agents such as lipids, occlusives, and humectants minimize damaging interactions between surfactants, and skin proteins and lipids, and thereby, reduce skin damage. In addition, these agents play an ameliorative role, replenishing the skin lipids lost during the wash period. The present review discusses the benefits of such agents and their respective roles in improving the overall health of the skin barrier.
...
PMID:Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. 1472 95
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination treatments and a comparison of different agents for these skin disorders are accumulating. The concomitant use of tazarotene with a mid-potency or high-potency corticosteroid enhances the efficacy in psoriatic plaques and reduces the risk of steroid-induced skin atrophy. Combining phototherapy with adjunctive tazarotene accelerates the clinical response and reduces the cumulative UVB or PUVA exposure load. Tazarotene applied once daily is superior to adapalene monotherapy in acne vulgaris and is efficacious in the treatment of photodamage. Novel therapeutic regimens such as short-contact therapy have been developed for both acne and psoriasis in order to diminish the major adverse events like
pruritus
, burning, local
skin irritation
and erythema.
...
PMID:Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. 1508 89
To evaluate the health impact of insecticides on Palestinian farm workers in the Gaza Strip, the study assessed biomarkers in farm workers who used organophosphorus insecticides. Serum cholinesterase and complete blood count were determined before and after spraying of organophosphorus insecticides. Burning sensations in eyes/face (62.5%),
itching
/
skin irritation
(37.5%), and chest symptoms (29.2%) were reported. Serum butyrylcholinesterase (SBuChE) was significantly decreased at the end of the work day. Burning sensations in eyes/face and skin rash were significantly associated with inhibition of SBuChE activity (p < 0.05). Younger workers were more affected. Leukocyte and platelet counts were increased and hemoglobin decreased significantly, reflecting acute poisoning. Monitoring of SBuChE and hematologic parameters of farm workers could be useful to predict and prevent health hazards of pesticides.
...
PMID:Adverse impact of insecticides on the health of Palestinian farm workers in the Gaza Strip: a hematologic biomarker study. 1587 90
Topical and oral retinoids have been successfully used in antipsoriatic therapy over the last 50 years. Development of more selective agents has led to an improved efficacy and safety profile. The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as
pruritus
, burning, local
skin irritation
, and erythema are limited to the skin and generally mild or moderate in severity. Although effective as monotherapy, evidence is accumulating that combining topical tazarotene with other established antipsoriatic therapies results in enhanced efficacy and reduced adverse events. In particular, concomitant use of topical tazarotene with a mid-potency or high-potency corticosteroid in the treatment of psoriatic plaques enhances efficacy and reduces the risk of corticosteroid-induced skin atrophy. Combination of phototherapy with tazarotene accelerates the clinical response and diminishes the cumulative UVB or psoralen plus UVA (PUVA) exposure load. Recently, an oral form of tazarotene has been developed. The results of completed phase III clinical trials of this agent indicate a beneficial effect in moderate to severe plaque psoriasis. Adverse events are generally of mild severity, and most of those observed, such as cheilitis and dry skin, are typical of hypervitaminosis A. Of note, oral tazarotene appears not to be associated with other adverse events that are typical of oral retinoids, including hypertriglyceridemia and hypercholesterolemia. However, since head-to-head trials with acitretin (the only retinoid currently approved for systemic therapy) have not been conducted, it is unclear whether tazarotene is any safer or more effective than acitretin. Moreover, the major drawback of oral tazarotene is teratogenicity, which may limit its use in female patients. Further studies evaluating long-term clinical outcomes with oral tazarotene and its use in combination therapies are awaited.
...
PMID:Receptor-selective retinoids for psoriasis: focus on tazarotene. 1660 89
To assess serum cholinesterase levels and symptoms among farm workers who used mainly organophosphorus pesticides in the Gaza Strip, the authors took blood samples from and administered symptom questionnaires to an occupational cohort of 48 field workers. The authors tested the workers for serum acetylcholinesterase and serum butyrylcholinesterase (SBuChE) levels at the beginning and end of each work day. The authors took 20 employees as referents. The mean activity of SBuChE of the farm workers at the end of the spraying day (X = 3.28+/-0.12 kU/l) was lower by 13.2% than that of the referents at the end of the follow-up day (3.78+/-0.20 kU/l). Many symptoms were self-reported by farm workers. Certain symptoms, such as
itching
,
skin irritation
, and a burning sensation in eyes or face, were significantly associated with cholinesterase inhibition. A greater end-of-day reduction in SBuChE activity occurred in younger workers, those workers mixing pesticides, and with day of direct re-entry to the workplace. The authors detected alterations in some blood indexes. The study confirmed the finding that illness in pesticide workers exposed to organophosphorus pesticides can occur with trivial reductions in cholinesterase.
...
PMID:Hematological biomarkers in farm workers exposed to organophosphorus pesticides in the Gaza Strip. 1729 Aug 43
As yet no transdermal topical formulations have been developed for the treatment of chronic
itch
. We developed a formulation containing 2 mg butorphanol tartrate in 100 microl purified water encapsulated into multilamellar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate
skin irritation
of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic
pruritus
.
...
PMID:In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. 1870 99
Primary hyperidrosis (PH) is a disorder characterized by excessive eccrine sweat gland production that primarily involves the axillae as well as palms and soles. Common first-line topical treatment for PH consists of aluminum salts (AS) that act by physically blocking eccrine sweat gland ducts. However, primary irritant contact dermatitis is a common side effect of AS treatment. Recently, a new low-residue, thermophobic foam formulation containing 20% aluminum sesquichlorohydrate has been developed (Nidrox, Mipharm S.p.A.). To evaluate the local tolerability and efficacy of 20% aluminum sesquichlorohydrate foam in the treatment of axillary and palmar PH. Twenty subjects affected by PH were enrolled in a multicenter, open-label study. Local tolerability was evaluated by physicians assessing
itching
, burning, and
skin irritation
using a four-point score (from 0: no symptoms to 3: severe symptoms).
Skin irritation
was quantified with a visual score. Efficacy was assessed by means of Minor test score using a four-point score (range 0-3). The foam was applied to clean dry skin, every night during the first 2 weeks and three times a week during the following 2 weeks. Clinical evaluations were performed at baseline, at day 14 and at day 28. Patients were monitored throughout the study for adverse events. All 20 subjects completed the study. The foam induced a significant reduction of the Minor score in comparison with baseline values (p = 0.0002) both at day 14 and at day 28. At the end of the 4-week treatment period, the foam reduced eccrine sweating by 61% (Minor score: 3.3 vs. 8.5). No
skin irritation
was observed during the trial except for one subject who experienced a mild and transient
itching
sensation. No other side effects were reported during the study. This new foam appears to be an effective and well-tolerated topical treatment in reducing sweating in patients with axillary and palmar PH.
...
PMID:An open-label tolerability and efficacy study of an aluminum sesquichlorohydrate topical foam in axillary and palmar primary hyperhidrosis. 1872 13
Topical application of ceramides is reported to improve the structure and texture of the skin. Synthetic pseudo-cermaide, SLE66 has been shown to reduce dryness/scaling/
itching
of human skin. Although efficacy of topically applied ceramides and their analogs has been investigated to some extent, safety information is scarce. The objective of the present investigation was to evaluate potential adverse effects of SLE66. The oral LD(50) of SLE66 in rats and mice was >5000 mg/kg, while dermal LD(50) in rats was >2000 mg/kg. In animal and human studies, SLE66 did not cause
skin irritation
or sensitization. SLE66 does not possess phototoxicity or photosensitization potentials. Instillation of SLE66 into rabbit eye elicited transient conjunctival irritation. In 28 day repeat-dose studies, administration of SLE66 via gavage (daily) or by dermal application (five days/week) to Sprague Dawley rats at levels up to 1000 mg/kg/day did not cause mortality or morbidity. Compared to the controls, the clinical condition of the animals, body weights, feed consumption, hematology, clinical chemistry, organ weights, and gross necropsy findings were unaffected by oral or dermal administration of SLE66. The no-observed-adverse-effect level (NOAEL) for systemic toxicity following oral or dermal administration of SLE66 was 1000 mg/kg/day (the highest level tested).
...
PMID:Safety studies of pseudo-ceramide SLE66: acute and short-term toxicity. 1905 1
Studies were conducted on the efficacy of Olyset nets-a long-lasting insecticidal net (LLIN) factory treated with 2% (w/w) permethrin on malaria transmission in an area under the influence of pyrethroid susceptible vector species Anopheles culicifacies and A. fluviatilis in Sundargarh District, Orissa, India. The study area comprised 22 villages that were randomized into three clusters and designated as Olyset net, untreated net, and no net area. Malaria incidence in the study population was measured through longitudinal active surveillance at fortnightly intervals. There was a reduction of 65-70% in malaria incidence in Olyset net area as compared to the control areas. The attack rate of Plasmodium falciparum or number of episodes per person per year in different age groups also showed significant reduction in Olyset net area as compared to untreated net and no net areas. Cross-sectional point prevalence surveys showed 45.7% reduction of malaria prevalence in Olyset net users, whereas there was an increase of 33.3% and 51% in untreated net and no net villages respectively. The compliance rate of Olyset net usage in the study population was 80-98% during different months, whereas it was between 70% and 90% for untreated nets. There were minimal complains of
skin irritation
(4%),
itching
(8%) and eye irritation (1.2%). However, these effects were only transitory in nature lasting for few hours of the first usage. Olyset nets also provided collateral benefits in terms of relief not only from mosquitoes and malaria but also from other household pests such as head lice, bed bugs, cockroaches, ants and houseflies. The Olyset nets were found to be safe to humans as no adverse event was recorded in the net users that can be attributed to the use of net. The study showed that Olyset nets are effective personal protection tool that can be used in a community based intervention programme.
...
PMID:Efficacy of permethrin treated long-lasting insecticidal nets on malaria transmission and observations on the perceived side effects, collateral benefits and human safety in a hyperendemic tribal area of Orissa, India. 1964 15
<< Previous
1
2
3
4
5
6
Next >>